WHO ICTRP trial
The TEAM trial (Tasigna efficacy in advanced melanoma): A phase II, open label…
NL-OMON37871 · Overview of Medical Research in the Netherlands (NL-OMON)
Key facts
| Trial ID | NL-OMON37871 |
|---|---|
| Public title | The TEAM trial (Tasigna efficacy in advanced melanoma): A phase II, open label, multi-center, single-arm study to assess the efficacy of Tasigna® in the treatment of patients with metastatic and/or inoperable melanoma harboring a c- Kit mutation |
| Scientific title | The TEAM trial (Tasigna efficacy in advanced melanoma): A phase II, open label, multi-center, single-arm study to assess the efficacy of Tasigna® in the treatment of patients with metastatic and/or inoperable melanoma harboring a c- Kit mutation - TEAM (am2) |
| Primary sponsor | Novartis |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Study type | Interventional |
| Phase | 2 |
| Countries | Argentina;Belgium;Brazil;Canada;China;Germany;Italy;Netherlands ;Poland;Singapore;Sweden;Switzerland;Thailand;United States of America |
| Conditions | disseminated skin cancer metastatic melanoma;10040900;disseminated skin cancer;metastatic melanoma |
| Interventions | The dose of nilotinib will be 400 mg orally b.i.d. administered continuously. Dose reduction is required in cases of clinically relevant toxic effects (to 400 mg q.d.) provided criteria for withdrawal from study drug are not met, which is… |
| Registration date | Mar 16, 2012 |
| Target size | 3 |
| Secondary IDs | 2009-015514-21;NCT01028222;NL38641.091.11 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: